Combination may improve antitumor activity in certain patients with B-cell NHL
Click Here to Manage Email Alerts
CHICAGO — Loncastuximab tesirine and polatuzumab vedotin may show improved efficacy and manageable toxicity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, according to research presented at ASCO Annual Meeting.
The study, presented by Brian Hess, MD, assistant professor at Medical University of South Carolina, is a phase 1b open-label study (LOTIS-7) that combined loncastuximab tesirine (Zynlonta, ADC Therapeutics) — a CD19-directed, antibody-drug conjugate — and polatuzumab vedotin (Polivy, Genentech) — a CD79b-directed antibody-drug conjugate. CD20×CD3 T-cell engaging antibodies and loncastuximab tesirine target different antigens, according to researchers.
“In fact, preclinical models may have shown that the combination of loncastuximab tesirine plus polatuzumab vedotin improved antitumor activity compared with either monotherapy alone. In addition, combining loncastuximab tesirine with bispecific antibodies is expected to increase antitumor activity,” Hess said.
LOTIS-7 will enroll approximately 200 patients with relapsed/refractory B-cell non-Hodgkin lymphoma in part one (dose escalation with 60 patients) and part two (dose expansion, 140 patients). Twelve patients have been enrolled and nine treated in the loncastuximab tesirine plus polatuzumab vedotin arm.
“In conclusion, the safety, tolerability and anticancer activity of loncastuximab tesirine in combination with other anticancer agents are being assessed in patients with relapsed/refractory B-cell non-Hodgkin lymphoma,” Hess said.
Collapse
Hess B, et al. Abstract TPS7581. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Read more about
Click Here to Manage Email Alerts